Companies / VBS

VECTUS BIOSYSTEMS LIMITED

ASX:VBSPharmaceuticals, Biotechnology & Life Sciences
61.7M shares on issueASX (delayed) · as of 28 July 2026$0.15price · delayed$9.3Mmarket cap · indicative
C
Dilution grade

Runway 2–4 quarters; share count grew 16% in 24 months; 2 cash raises in 24 months

Cash runway3.1 quarters of funding
Share-count growth (24m)15.9%
Raise cadence (24m)2 cash raises
Options & rights overhang1.9% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

VECTUS BIOSYSTEMS LIMITED's ordinary share count grew 15.9% between May 2024 and June 2026, to 62M shares. The company raised capital twice in that period for total disclosed proceeds of A$1.6M, most recently a A$791K placement in May 2026. Options and rights on issue could convert into 1M new shares, equal to 1.9% of the current share count, with 0% in the money at present and the nearest expiry in November 2026. At the June 2026 quarter the company reported A$653K in available cash, representing about 3.1 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
1.9%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
3.1 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 61.7M per ASX (delayed) (28 July 2026).
55.0M57.5M59.9MDec 24Sept 25July 26Cash raise · 22 May 2026Cash raise · 21 May 2026

Cash runway

3.1 qtrs
Two to four quarters of funding at the recent spend rate.
$653k available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
26 June 20262A · quoted issueVBS : ORDINARY FULLY PAID61.7MAppendix 2A
27 May 20262A · quoted issueVBS : ORDINARY FULLY PAID61.5MAppendix 2A
12 May 20262A · quoted issueVBS : ORDINARY FULLY PAID53.6MAppendix 2A
8 May 20262A · quoted issueVBS : ORDINARY FULLY PAID53.5MAppendix 2A
8 May 20263G · unquotedVBS : ORDINARY FULLY PAID53.4MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

$791k
Placement
22 May 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

1.9%
Total overhang · of current shares
0.0%
In the money · at current price
1.2M
Potential new shares
Nov 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

No director dealing notices (Appendix 3Y) on record.
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026$PQuarterly Activities & Appendix 4C Cash Flow Reports
12 July 2026VBS Engages CHRS as Regulatory Agent for FDA Submissions
26 June 2026Cleansing Notice
26 June 2026Application for quotation of securities - VBS
16 June 2026CEO Investor Webinar
29 May 2026Change in substantial holding
27 May 2026Change in substantial holding KHPL
27 May 2026Cleansing Notice
27 May 2026Application for quotation of securities - VBS
22 May 2026Proposed issue of securities - VBS
22 May 2026$PPlacement of Shares
14 May 2026Updated Corporate Presentation
12 May 2026Cleansing Notice
12 May 2026Application for quotation of securities - VBS
8 May 2026Cleansing Notice
8 May 2026Application for quotation of securities - VBS
8 May 2026Notification regarding unquoted securities - VBS
7 May 2026$PAppointment of Dr Tara Speranza as CEO & CTO
30 Apr 2026$PQuarterly Activities & Appendix 4C Cash Flow Reports
13 Apr 2026$PVB4-P5 Renal Compound Transaction Settled

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.